STAT Plus: A preliminary new method could restore the brain cells Parkinson’s disease patients lost
Researchers developed a new method for transforming brain cells that can completely eliminate Parkinson’s disease…
Category: STAT Plus
STAT Plus: Pharmalittle: WHO sets goals for distributing Covid-19 treatments; new warnings urged on diabetes drugs
Hello, everyone, and how are you today? A bright shiny sun and cool breezes are…
STAT Plus: Yumanity Therapeutics, Merck strike deal aimed at developing new medicines for neurodegenerative disease
Yumanity Therapeutics, a small neuroscience-focused startup co-founded by longtime biotech executive Tony Coles, is pairing…
STAT Plus: FDA urged to heighten safety warnings on common type 2 diabetes drugs
A consumer advocacy is urging the Food and Drug Administration to heighten warnings about a…
STAT Plus: STAT+ Conversations: The Readout LOUD, Live!
Editor’s note: The livestream of this conversation will be embedded below at 1 p.m. ET. …
STAT Plus: As approval decision nears, fate of Intercept’s NASH drug clouded by murky FDA review delays
On Friday, the Food and Drug Administration is supposed to announce its decision on whether…
STAT Plus: Pharmalittle: Sanofi steps up Covid-19 vaccine efforts; has a successor to FDA’s Janet Woodcock been found?
Top of the morning to you. And a steamy one, it is. In fact, there…
STAT Plus: Myovant endometriosis drug meets its goal in a second late-stage trial, company says
A combination pill from Myovant Sciences met its primary goal of reducing pain from endometriosis,…
STAT Plus: Sana Biotechnology, the secretive startup, lays (some) cards on the table
After years of rumors, Sana Biotechnology is officially biotech’s newest unicorn. The company announced Tuesday…
STAT Plus: The new Janet: The FDA turns to a quiet problem-solver who brings expertise — and a little controversy
WASHINGTON — Janet Woodcock, one of the FDA’s most powerful regulators, has an almost mythic…
STAT Plus: After a bribery scandal in China, GSK found a suspected whistleblower. The real one is still waiting in the shadows
Alarmed that colleagues were bribing Chinese doctors and giving kickbacks to hospital workers to boost…
STAT Plus: A Chinese drug maker scores a big clinical trial win with a novel diabetes therapy
Two years ago, Hua Medicine turned to the public markets to help finance its ambitious…
.jpg)
STAT Plus: Pharmalittle: Will a Covid-19 vaccine protect the elderly? Generic remdesivir to cost up to $79 a dose
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Can a prescription video game actually make money? Akili is about to find out
Akili Interactive Labs proved last week that it could convince the Food and Drug Administration…
STAT Plus: A crucial study of Bellus Health’s chronic cough drug reads out soon. Here’s what you need to know
Bellus Health, a small Canadian drug maker, is seeking to develop a potential blockbuster medicine…
STAT Plus: Pharmalittle: Europe nears a deal for J&J Covid-19 vaccine; Biogen loses a big patent case
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Finch touts positive results for its microbiome pill for C. diff infections
Three-quarters of the people who got Finch Therapeutics’ microbe-based pill for potentially deadly C. difficile…
STAT Plus: A ‘semi-wartime’ effort: Thermo Fisher COO on adapting the business to a Covid-19 world
Way back in January, Thermo Fisher Scientific (TMO), the world’s largest maker of scientific tools,…
STAT Plus: Vertex and Canada hold talks over cystic fibrosis drug, but a deal for newer medicine remains out of reach
The icy relationship between Vertex Pharmaceuticals (VRTX) and the Canadian government is showing signs of…
STAT Plus: New findings about little-studied cellular compartments could help make chemo more effective
Getting the right drug to the right place at the right time has been the…
STAT Plus: Clinical trial costs to develop a new drug may actually be rather modest — or so one study suggests
For years, the pharmaceutical industry has maintained that the costs to develop medicines accounts for…
STAT Plus: Court invalidates Biogen’s patent on blockbuster multiple sclerosis drug
Shares of Biogen fell Thursday after a federal court judge ruled in favor of generic…
STAT Plus: Pharmalittle: Trump pushes for Covid-19 vaccine by year’s end; Americans fear pharma will keep raising drug prices
Hello, everyone, and how are you today? We are doing just fine, thank you, despite…
STAT Plus: A majority of Americans fear pharma will use Covid-19 as an excuse to raise prices
Amid a race to find therapies and vaccines to combat Covid-19, a new poll finds…
STAT Plus: Trump administration seeks to encourage ‘value-based’ drug pricing deals with new proposal
WASHINGTON — The Trump administration wants to revamp certain Medicaid rules about drug prices in…
STAT Plus: California attorney general says FTC failed to follow ‘best practices’ in approving AbbVie-Allergan deal
Arguing that the Federal Trade Commission did not follow “best practices” in approving AbbVie’s recent…
STAT Plus: CAR-T cells, better known as cancer drugs, show promise against aging in lab mice
Scientists are still trying to get CAR-T cells to work as well in solid tumors…
STAT Plus: BioMarin’s hemophilia gene therapy continues to prevent bleeding at four years
BioMarin’s experimental hemophilia gene therapy, which is expected to be approved by U.S. regulators in…
STAT Plus: Pharmalittle: White House says Covid-19 vaccine will be free to the ‘vulnerable’; vaccine makers hunt for glass vials
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT Plus: As quality concerns rise, FDA report shows Indian drug plants inspected more often — and had more problems
As concerns mount over the quality of the pharmaceutical supply chain, the Food and Drug…
STAT Plus: Eli Lilly gets an edge against Pfizer in adjuvant breast cancer
Eli Lilly announced Tuesday that adding its drug Verzeneio to hormone blockers decreased the risk…
STAT Plus: Royalty Pharma, a drug company that doesn’t develop drugs, shatters IPO record
Royalty Pharma, a business built on investing in other people’s medicines, raised $2.2 billion in…
STAT Plus: Ramping up pressure on Elsevier, University of California strikes landmark research access deal with publisher of Nature journals
The University of California has reached a landmark deal with the world’s second largest academic…
STAT Plus: Smart pill maker Proteus files for bankruptcy, reveals it has held acquisition talks with Otsuka
Smart pill maker Proteus Digital Health on Monday filed for Chapter 11 bankruptcy, the latest…
STAT Plus: Supreme Court deals a series of blows to generic drug companies
It’s a bad run for generic drug companies at the Supreme Court. The court on…
STAT Plus: Pharmalittle: Cheap steroid reduced deaths in severe Covid-19 patients; what the FDA decision on hydroxychloroquine means
Rise and shine, everyone, another very busy day awaits. Even so, there is nothing like…
STAT Plus: A YouTube ‘hit job’ about a Catalyst Pharma rival is posted amid its battle with the FDA
In a move that resembles a scare tactic, a newly posted YouTube video shows a…
STAT Plus: Pharmalittle: Lilly begins studying RA drug for Covid-19; AstraZeneca to provide Europe 400 million vaccine doses
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Momenta Pharma drug improves symptoms in patients with myasthenia gravis
Momenta Pharmaceuticals reported Monday that in a mid-stage clinical trial, an experimental medicine significantly improved…
STAT Plus: A would-be chain of cancer centers wants to treat patients with Right to Try drugs, raising ethical questions
In an unusual move, a private equity firm is soliciting investors to help create a…
STAT Plus: What’s at stake for industry in the pharmaceutical Space Race for a Covid-19 vaccine
The Trump administration’s move to pick five companies as finalists in the quest to develop…
STAT Plus: As efficacy of Constellation’s blood cancer drug wanes, the debate over its future ratchets higher
The response rate to an experimental myelofibrosis drug is falling, Constellation Pharmaceuticals, the drug’s maker,…
STAT Plus: Antimicrobials benefited from expedited FDA programs more than other drugs
Amid concerns over the need for more antimicrobials, a new analysis finds these medicines benefited…
STAT Plus: PhRMA’s top communicator, a fierce defender of the industry, leaves for ExxonMobil
The top spokesperson for the drug industry’s main lobbying group in Washington is taking a…
STAT Plus: Pharmalittle: U.S. Chamber wants transparency around Covid-19 vaccines; EU to pump billions into vaccine deals
And so, another working week will soon draw to a close. If you are surprised…
STAT Plus: Agios drug demonstrates strong response in patients with inherited blood disorder
Agios Pharmaceuticals on Friday reported positive results from the first clinical trial of its lead…
STAT Plus: New data in sickle cell show biotech companies tackling disease in novel ways
Sickle cell disease features prominently at this year’s virtual meeting of the European Hematology Association,…
A new embryo-like model could help scientists study the ‘black box’ of early human development
Researchers have developed the first-ever embryo-like model from human embryonic stem cells, a workaround that…
STAT Plus: Pharmalittle: Pfizer CEO says Covid-19 vaccine price won’t be huge; Lilly antibody therapy may be ready by fall
Hello, everyone, and how are you today? Cloudy skies are hovering this morning over the…
STAT Plus: Verve, raising another $63 million, seeks to advance gene-editing treatment for heart disease
Verve Therapeutics, a Cambridge biotech that wants to use gene-editing to lower cholesterol, said Thursday…